èšåºæ®µéã®å
ç«è
«çåŠäŒæ¥ã§ãã Agenus Inc. ã¯ãç±³åœããã³äžçäžã§å
ç«è
«çåŠè£œåã®çºèŠãšéçºãè¡ã£ãŠããŸããå瀟ã¯ãå®å
šããããã³ããåã¢ãã¯ããŒãã«æäœã®èå¥ã®ããã®æäœçºçŸãã©ãããã©ãŒã ã§ãã Retroocyte Display ãšãã£ã¹ãã¬ã€æè¡ãæäŸããŠããŸããå瀟ã¯ããããã¡ãŒãžã¯ã¯ãã³åè£ãåææ°æåã§ãã AutoSynVaxãè
«çæ²»ççšã¯ã¯ãã³åè£ã§ãã PhosPhoSynVaxããµããã³ããŒã¹ã®ã¯ã¯ãã³ã¢ãžã¥ãã³ãã§ãã QS-21 Stimulon ã¢ãžã¥ãã³ããããªãã¯ã¯ãã³ããã°ã©ã ãéçºããŠããŸããå瀟ã¯ãŸãã第 2 éžæåå®®é žããã®æ²»çãç®çãšãã第 II çžèšåºè©Šéšäžã®æ PD-1 æ®æè¬ã§ãã Balstilimabãçšé挞å¢ç ç©¶ã®ç¬¬ 1/2 çžèšåºè©Šéšäžã®æ CTLA-4 åäžç¹ç°æ§æäœã§ãã AGEN1181ã第 1 çžèšåºè©Šéšäžã®æ CD137 åäžç¹ç°æ§æäœã§ãã AGEN2373 ãéçºããŠããŸããå瀟ã¯ãçŸåšç¬¬1çžèšåºè©Šéšäžã®å¶åŸ¡æ§T现èãæ¯æžãããæ°èŠäºéç¹ç°æ§æäœAGEN1223ã第1çžèšåºè©Šéšãå®äºããè
«ç埮å°ç°å¢èª¿æŽæCD73/TGFβ TRAPäºéç¹ç°æ§æäœAGEN-1423ãæTIGITäºéç¹ç°æ§æäœAGEN1777ãæTIGITåäžç¹ç°æ§æäœAGEN1327ãéçºããŠãããããã«ãæGITRåäžç¹ç°æ§æäœINCAGN1876ãæOX40åäžç¹ç°æ§æäœINCAGN1949ãæTIM-3åäžç¹ç°æ§æäœINCAGN2390ãæLAG-3åäžç¹ç°æ§æäœINCAGN2385ãILT4ãæšçãšããåäžç¹ç°æ§æäœMK-4830ãããã³COVID-19é¢é£èºçã®æ²»çè¬ãšããŠç¬¬1çžèšåºè©Šéšäžã®iNKT现èAGENT 797ãéçºããŠãããå€çºæ§éªšé«è
«/BçŽ°èæªæ§è
«çããã³åºåœ¢è
«çã®æ²»çè¬ãšããŠåèšåºæ®µéã«ãããŸããå瀟ã¯ãIncyte CorporationãMerck Sharpe & DohmeãRecepta Biopharma SAãããã³Gilead Sciences, Inc.ãšææºããŠããŸããå瀟ã¯ä»¥åã¯Antigenics Inc.ãšããŠç¥ãããŠããŸãããã2011幎1æã«Agenus Inc.ã«ç€Ÿåã倿ŽããŸãããAgenus Inc.ã¯1994幎ã«èšç«ãããããµãã¥ãŒã»ããå·ã¬ãã·ã³ãã³ã«æ¬ç€Ÿã眮ããŠããŸãã